PT  - JOURNAL ARTICLE
AU  - Z Hao
AU  - D A Cooney
AU  - D Farquhar
AU  - C F Perno
AU  - K Zhang
AU  - R Masood
AU  - Y Wilson
AU  - N R Hartman
AU  - J Balzarini
AU  - D G Johns
TI  - Potent DNA chain termination activity and selective inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxyuridine-5'-triphosphate.
DP  - 1990 Feb 01
TA  - Molecular Pharmacology
PG  - 157--163
VI  - 37
IP  - 2
4099  - http://molpharm.aspetjournals.org/content/37/2/157.short
4100  - http://molpharm.aspetjournals.org/content/37/2/157.full
SO  - Mol Pharmacol1990 Feb 01; 37
AB  - 2',3'-Dideoxyuridine (ddUrd) exhibits poor if any anti-human immunodeficiency virus (HIV) activity in ATH8 and MT-4 cells. This is in agreement with the failure of ddUrd to be efficiently anabolized intracellularly to its 5'-triphosphate metabolite. However, 2',3'-dideoxyuridine-5'-triphosphate (ddUTP) proved to be a potent and selective inhibitor of the reverse transcriptase of HIV (Ki, 0.05 microM) and avian myeloblastosis virus (Ki, 1.0 microM). Bacterial DNA polymerase I, mammalian DNA polymerase alpha, terminal deoxyribonucleotidyl transferase, and Moloney murine leukemia virus reverse transcriptase were resistant to ddUTP. ddUTP is incorporated into the growing DNA chain principally at dTTP sites and inhibits further elongation. The potential of ddUTP as an anti-HIV therapeutic agent merits further investigation. However, to achieve this goal, it will be necessary to resort to techniques capable of delivering preformed phosphorylated ddUrd to the susceptible cells.